Cancer claims the lives of 1.5 million Europeans every year—a staggering number that demands immediate action. But here’s where it gets controversial: despite Europe’s world-class scientific talent and cutting-edge research, the journey from groundbreaking discovery to life-saving treatment remains frustratingly fragmented. Why is this still happening?
In a powerful LinkedIn post, Johanna Joyce, Professor at the University of Lausanne and Full Member of the Ludwig Institute for Cancer Research, joins renowned experts René Bernards, Anton Berns, and Michael Baumann in a call to arms. Their Nature Cancer commentary (https://www.nature.com/articles/s43018-025-01062-6) highlights a stark reality: while Europe excels in scientific innovation, the support for basic research, clinical translation, prevention, and biotech development is alarmingly uneven across the continent. Is Europe truly prioritizing its potential to save lives?
Joyce and her co-authors argue that the engine of innovation—basic, curiosity-driven research—is under increasing pressure. Meanwhile, early-career scientists and innovators often lack the support they need to thrive. And this is the part most people miss: patients, the very heart of cancer research, are rarely integrated as true partners in decision-making processes. Shouldn’t those most affected have a seat at the table?
In their article, the authors propose seven strategic priorities to reshape Europe’s cancer research landscape. These include sustained investment in foundational research, stronger academic-industry collaboration, and empowering patients as active participants in research and clinical care. By implementing these measures, Europe could not only maintain its scientific leadership but also accelerate progress for patients across the entire cancer continuum.
The solutions are within reach—Europe has the talent, the infrastructure, and the expertise. What’s missing? A long-term vision, political commitment, and the will to ensure scientific breakthroughs translate into faster, fairer, and more effective treatments for those who need them most. Is Europe ready to step up and lead the fight against cancer?
This isn’t just a call for change—it’s a challenge to rethink how we approach one of humanity’s greatest challenges. What do you think? Are the authors’ proposals enough, or is there more Europe should be doing? Let’s spark a conversation in the comments below. (For more insights from Johanna Joyce, visit https://oncodaily.com/tag/johanna-joyce.)
